From the Guidelines
Cortisone eye drops, specifically loteprednol etabonate (Alrex), are the primary corticosteroid option for treating severe symptoms of allergic conjunctivitis. The use of corticosteroid eye drops should be reserved for more severe symptoms due to the potential for vision-threatening side effects, such as cataract formation, elevated intraocular pressure (IOP), and secondary infections 1. Some key points to consider when using corticosteroid eye drops include:
- They should only be used under medical supervision due to the risk of serious side effects
- Loteprednol etabonate (Alrex) has a reduced risk of causing increased IOP compared to other ocular corticosteroids
- Dosing and treatment duration will vary depending on the specific condition being treated and the severity of symptoms
- It is essential to complete the full course of treatment as directed by an eye care provider, even if symptoms improve before finishing the medication 1. Other options, such as antihistamines, mast cell stabilizers, and NSAIDs, may be more suitable for mild to moderate symptoms of allergic conjunctivitis, and can be used in conjunction with or instead of corticosteroid eye drops, depending on the individual case 1.
From the FDA Drug Label
Loteprednol Etabonate Ophthalmic Suspension, 0.2% contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. The names of Cortisone eye drops mentioned are:
From the Research
Cortisone Eye Drop Names
- Loteprednol etabonate 3, 4, 5, 6
- Prednisolone 4, 7
- Prednisolone acetate 4, 6
- Dexamethasone 4, 6
- Triamcinolone acetonide 4
- Fluocinolone acetonide 4
Characteristics of Cortisone Eye Drops
- Loteprednol etabonate has a low propensity to cause corticosteroid-related adverse effects, such as elevated intraocular pressure (IOP) 3, 6
- Prednisolone is effective in controlling postoperative intraocular inflammation 7
- Loteprednol etabonate is designed to be rapidly converted to an inactive, nontoxic metabolite, thus minimizing adverse effects 5